Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Amyotrophic Lateral Sclerosis (ALS) Clinical Trials

A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

Phase

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

One of the major disease features of ALS is the progressive death of motor neurons. Human, rodent and stem cell-based model studies support the hypothesis that neuronal hyperexcitability may contribute to neurodegeneration in both sporadic and familial ALS. The investigators are doing this research study to find out whether retigabine ...

Phase

Safety and Biomarker Study of EPI-589 in Subjects With ALS

Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal phase to determine duration of treatment response.

Phase

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS and evidence of elevated systemic inflammation. Subjects will be allocated (1:1) to NP001 and placebo. Drug or placebo will be given intravenously.

Phase

Efficacy and Safety of Plasma Exchange With Albutein 5% in Patients With Amyotrophic Lateral Sclerosis

This is a phase IIa, prospective, open-label, single-arm pilot study to evaluate the efficacy and safety of PE with Albutein 5% in subjects with ALS. The planned enrollment is 10 subjects who have a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria. Enrolled subjects ...

Phase

Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response

This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive wasting and weakness of both upper and ...

Phase

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease for which there is no cure. Multiple lines of evidence have implicated oxidative stress in the pathophysiology of ALS. Urate (uric acid) is an endogenous antioxidant system, and urate may serve as a major defense against oxidative stress. Urate has emerged ...

Phase

Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients

Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a fatal progressive neurodegenerative disease affecting motor cortex, brainstem and spinal cord leading to motor neuron death. It is a devastating disease of the anterior and lateral corticospinal tracts with approximately 3 years mean duration from symptoms onset to ...

Phase

Rapamycin Treatment for ALS

This is a phase II randomized, double-blind, placebo-controlled, multicenter clinical trial for people with ALS. The aim is to study the biological and clinical effect of Rapamycin (in two different doses) in addition to Riluzole on ALS patients through comparison with patients treated with Riluzole and placebo. Rapamycin has been ...

Phase